Kevin Tang’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-240,000
| Closed | -$766K | – | 2 |
|
|
2022
Q2 | $766K | Hold |
240,000
| – | – | 99.74% | 1 |
|
|
2022
Q1 | $1.02M | Hold |
240,000
| – | – | 99.61% | 1 |
|
|
2021
Q4 | $1.12M | Hold |
240,000
| – | – | 99.38% | 1 |
|
|
2021
Q3 | $958K | Hold |
240,000
| – | – | 99.17% | 1 |
|
|
2021
Q2 | $1.03M | Hold |
240,000
| – | – | 95.09% | 1 |
|
|
2021
Q1 | $1.02M | Hold |
240,000
| – | – | 94.79% | 1 |
|
|
2020
Q4 | $931K | Hold |
240,000
| – | – | 92.73% | 1 |
|
|
2020
Q3 | $967K | Hold |
240,000
| – | – | 78.24% | 1 |
|
|
2020
Q2 | $1.02M | Hold |
240,000
| – | – | 79.29% | 1 |
|
|
2020
Q1 | $1.01M | Hold |
240,000
| – | – | 80.13% | 1 |
|
|
2019
Q4 | $943K | Hold |
240,000
| – | – | 11.17% | 2 |
|
|
2019
Q3 | $2.11M | Hold |
240,000
| – | – | 75.03% | 1 |
|
|
2019
Q2 | $2.22M | Hold |
240,000
| – | – | 75.87% | 1 |
|
|
2019
Q1 | $1.54M | Buy |
+240,000
| New | +$1.56M | 61.84% | 1 |
|
Kevin Tang's LJPC Position: Q3 2022 in Review
Kevin Tang sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 240,000 shares — an estimated $766K sold.
Kevin Tang first reported a position in LJPC in Q1 2019 and held it in 14 quarters. The position peaked at $2.22M in Q2 2019. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Kevin Tang reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Kevin Tang sold 240,000 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $766K.
- Kevin Tang first reported a position in La Jolla Pharmaceutical Company in Q1 2019 and held it in 14 quarters.
- Kevin Tang's La Jolla Pharmaceutical Company position peaked at $2.22M in Q2 2019.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Kevin Tang's 13F filing for Q3 2022, filed 14 Nov 2022.